PA-BOOMI
16.5.2023 16:01:30 CEST | Business Wire | Press release
BoomiTM, the intelligent connectivity and automation leader, today announced Boomi AI – a first-of-its-kind, simplified user experience that harnesses generative AI to connect and integrate applications, data, processes, people, and things across organizations – creating business outcomes faster than ever before.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005335/en/
Boomi Changes the Integration and Automation Game With Boomi AI (Graphic: Business Wire)
“The introduction of Boomi AI marks yet another milestone in our long history of pioneering innovation in the integration industry,” said Ed Macosky, Chief Product Officer at Boomi. “We pioneered the first low-code, cloud-native integration platform as a service (iPaaS) to disrupt the middleware market 20+ years ago. Then, over a decade ago, Boomi pioneered AI-assisted development with the launch of Boomi Suggest, which further disrupted the market. Now, we are taking our intelligent integration and automation platform to the next level by making it AI-first – enabling AI to responsibly build and complete integrations, and transform automation for our customers.”
In today’s constantly changing market, organizations are making substantial investments to modernize their digital operations. According to IDC, global spending on AI will increase by 26.9% in this next year alone. However, disconnected ecosystems make it difficult for IT teams to focus on strategic initiatives. Fragmented tools, applications, and data can cause confusion and coordination issues, as teams lack a centralized platform for integration, API management, orchestration, and automation, resulting in time spent on maintenance, not innovation.
Boomi’s AI engine is fueled by the company’s approximately 20,000 customers – the largest customer base among integration platform vendors. Boomi AI leverages anonymized metadata, patterns, and best practices from the 200 million integrations made with the Boomi platform to train the AI models to create high-quality integrations across various business processes and applications, such as data management, customer experience optimization, or supply chain processes.
“Boomi’s extensive knowledge base makes our AI engine far more advanced than the AI-assisted development tools available today. It also benefits users by continuously testing patterns to ensure optimal integration design and root out risks and errors early, enabling customers to achieve tremendous gains in efficiency, operational improvements, and other desirable business outcomes,” added Macosky.
With Boomi AI, organizations can:
Design Connections: Boomi AI can design integration processes, application programming interfaces, and master data models with built-in best practices from millions of successful use cases, through a quick command, like, “Connect my CRM and invoice systems.”
Optimize Operations: With Boomi AI’s actionable intelligent insights, users can solve problems proactively, facilitate predictive maintenance, automate updates, and allocate optimal resources to enable software to efficiently self-manage itself. These insights, like “A data attribute in Salesforce has changed. Would you like to apply it across your systems?” make previously menial tasks quick and easy.
Orchestrate Experiences: Boomi AI can interpret intent behind desired business outcomes to orchestrate processes across applications. It enhances decision-making, simplifies tasks, and improves engagement while providing audit history and prompts to confirm intent so that decisions and outcomes are always explainable, creating even greater synergies between IT and the business. With a simple prompt like “Automate invoice processing,” IT teams and business leaders can focus on what matters most.
Enable Responsible AI Development: Boomi’s AI algorithms are trained to avoid biases and unfairness with established ethical guidelines for the development and use of AI within the Boomi platform. These guidelines confirm that Boomi’s AI technology is used in a transparent and accountable manner, and that it does not violate any ethical principles or laws. Additionally, Boomi has achieved U.S. Federal Risk and Authorization Management Program (FedRAMP) Authorization Moderate, a government-wide program that provides a standardized approach to security assessment. Boomi AI does not store any customer-specific information of any kind.
“In today's fast-paced market, organizations need more powerful tools that enable them to outperform, and AI presents a potent new avenue to do this,” says Dion Hinchcliffe, VP and Principal Analyst of Constellation Research. “By embracing an important new AI-first approach, organizations can unlock new levels of efficiency, innovation, and competitive advantage, to immediately capture opportunity as well as ensure their business remains future-ready.”
As the pioneer of cloud-native integration platform as a service (iPaaS), Boomi celebrates a growing community of more than 100,000 members, and one of the largest arrays of global systems integrators (GSIs) in the iPaaS space. The company boasts a worldwide network of partners, including Accenture, Deloitte, SAP, and Snowflake; and works with the largest hyperscaler cloud service providers, including Amazon Web Services, Google, and Microsoft, among others.
Included on the Deloitte Technology Fast 500™ and Inc. 5000 lists as one of America’s fastest growing and most innovative technology companies, Boomi was recently named to Nucleus Research's list of “Hot Companies to Watch in 2023.” The company has also won numerous awards, including three International Stevie® Awards, for Company of the Year (two years in a row) and Product Innovation; the Gold Globee® Award in the Platform as a Service (PaaS) category; the Merit Award for Technology in the Cloud Services category; the Stratus Award as a Global Leader in Cloud Computing 2022; and received the prestigious 5-star rating in the CRN Partner Program Guide for two consecutive years.
Join the Boomi AI waitlist at boomi.ai.
Additional Resources
- Read more about accelerating outcomes with Boomi AI
- Learn more about the Boomi platform
- Explore the Boomiverse Community
- Follow Boomi on Twitter, LinkedIn, Facebook, and YouTube
About Boomi
Boomi aims to make the world a better place by connecting everyone to everything, anywhere. The pioneer of cloud-based integration platform as a service (iPaaS), and now a category-leading, global software as a service (SaaS) company, Boomi touts the largest customer base among integration platform vendors and a worldwide network of approximately 800 partners – including Accenture, Capgemini, Deloitte, SAP, and Snowflake. Global organizations turn to Boomi’s award-winning platform to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com.
© 2023 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005335/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
